The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
Jang Ho Cho
No Relationships to Disclose
 
Jong-Mu Sun
No Relationships to Disclose
 
Se-Hoon Lee
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Novartis
 
Jin Seok Ahn
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
 
Keon Uk Park
No Relationships to Disclose
 
Eun Joo Kang
No Relationships to Disclose
 
Yoon Hee Choi
No Relationships to Disclose
 
Ki Hwan Kim
No Relationships to Disclose
 
Ho Jung An
No Relationships to Disclose
 
Hyun Woo Lee
No Relationships to Disclose